Physician profile
Benjamin C Gans
NPI 1457771826
$3,898.66
in general payments reported to CMS, 2019-2025
30 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $412 · 2021: $827 · 2022: $329 · 2023: $563 · 2024: $794 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.35 | 2020-2025 | |
| Novo Nordisk INC | $484.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $462.04 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $415.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $244.81 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $177.52 | 2022-2025 | Rexulti |
| Allergan, INC. | $145.64 | 2019-2020 | |
| Pfizer INC. | $125.63 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.06 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $118.32 | 2021-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $112.13 | 2023-2025 | Trintellix |
| Amgen INC. | $105.64 | 2019-2024 | Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $83.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.61 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.82 | 2023-2024 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $55.96 | 2024-2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $55.86 | 2022-2025 | Nuzyra, Xhance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.92 | 2021-2025 | Xifaxan |
| Eisai INC. | $38.25 | 2020-2021 | |
| Inari Medical, INC. | $36.76 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $27.05 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Mylan Specialty L.P. | $21.75 | 2023 | Yupelri |
| Ironwood Pharmaceuticals, INC | $20.85 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.18 | 2025 | Fanapt |
| Astellas Pharma US INC | $19.93 | 2021 | |
| Abbott Laboratories | $19.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.14 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $16.43 | 2021 | |
| Amarin Pharma, INC. | $13.45 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.